Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,980 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach.
Kita J, Tamai M, Arima K, Kawashiri SY, Horai Y, Iwamoto N, Okada A, Koga T, Nakashima Y, Suzuki T, Yamasaki S, Nakamura H, Origuchi T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A. Kita J, et al. Among authors: suzuki t. Mod Rheumatol. 2013 Mar;23(2):254-9. doi: 10.1007/s10165-012-0646-5. Epub 2012 Jun 6. Mod Rheumatol. 2013. PMID: 22669596
Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T, Aramaki T, Nakashima M, Fujikawa K, Tsukada T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A. Kita J, et al. Among authors: suzuki t. Mod Rheumatol. 2012 Apr;22(2):195-201. doi: 10.1007/s10165-011-0511-y. Epub 2011 Sep 6. Mod Rheumatol. 2012. PMID: 21898075 Clinical Trial.
Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration.
Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Iwamoto N, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A. Kita J, et al. Among authors: suzuki t. Mod Rheumatol. 2012 Jun;22(3):346-52. doi: 10.1007/s10165-011-0522-8. Epub 2011 Sep 30. Mod Rheumatol. 2012. PMID: 21960457
Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.
Koga T, Okada A, Kawashiri S, Kita J, Suzuki T, Nakashima Y, Tamai M, Satoh K, Origuchi T, Iwamoto N, Yamasaki S, Nakamura H, Migita K, Ida H, Ueki Y, Eguchi K, Kawakami A. Koga T, et al. Among authors: suzuki t. Clin Exp Rheumatol. 2011 Sep-Oct;29(5):811-5. Epub 2011 Oct 31. Clin Exp Rheumatol. 2011. PMID: 22011479 Clinical Trial.
The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, Suzuki T, Nakashima Y, Tamai M, Arima K, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Ishimatsu Y, Mukae H, Kuwana M, Kohno S, Eguchi K, Aoyagi K, Kawakami A. Koga T, et al. Among authors: suzuki t. Rheumatology (Oxford). 2012 Jul;51(7):1278-84. doi: 10.1093/rheumatology/ker518. Epub 2012 Feb 29. Rheumatology (Oxford). 2012. PMID: 22378718 Free article.
Takayasu arteritis developing during treatment of ulcerative colitis with infliximab.
Horai Y, Satoru O, Lapalme-Remis S, Sumiyoshi R, Nakashima Y, Suzuki T, Okada A, Kawashiri SY, Ichinose K, Tamai M, Yamasaki S, Nakamura H, Takeshima F, Origuchi T, Kawakami A. Horai Y, et al. Among authors: suzuki t. Mod Rheumatol. 2013 May;23(3):572-6. doi: 10.1007/s10165-012-0684-z. Epub 2012 Jun 21. Mod Rheumatol. 2013. PMID: 22718488
21,980 results
You have reached the last available page of results. Please see the User Guide for more information.